Item 5. Other Information
Item 5.
Other Information .
None.
Item 6.
Exhibits.
44
Table of
Contents
Exhibit
Description
Incorporated By Reference
10.1
Master Services Agreement, dated September 9, 2022, by and between Factor Bioscience Inc. and the Company.
Exhibit 10.1 to Form 8-K filed on September 15, 2022
10.2*
Separation Agreement and General Release, dated August 24, 2022, by and between the Company and Kevin D’Amour.
Exhibit 10.1 to Form 8-K/A filed on September 1, 2022
10.3
Third Amended and Restated Exclusive License Agreement, dated November 1, 2020, by and between Factor Bioscience Limited and Novellus
Therapeutics Limited.
Filed herewith
31.1
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed herewith
31.2
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed herewith
32.1
Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Furnished herewith
32.2
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Furnished herewith
101.INS
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
Filed herewith
101.SCH
Inline XBRL Taxonomy Extension Schema Document
Filed herewith
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
Filed herewith
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
Filed herewith
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
Filed herewith
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
Filed herewith
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
* Management contract or compensation plan or arrangement
45
Table of
Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ETERNA THERAPEUTICS INC.
Date: November 14, 2022
By:
/s/ Andrew Jackson
Andrew Jackson
Chief Financial Officer
(on behalf of the Registrant and as Principal Financial Officer)
46
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.